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A case of Ameloblastic Fibrosarcoma Transformed from Ameloblastic Fibro-odontoma
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Ameloblastic fibrosarcoma (AFS) is an extremely rare malignant odontogenic tumor characterized with benign ameloblastic cells islands
and malignant mesenchymal component. While two-thirds of AFS seem to arise de novo, but one-third develops from recurrent ameloblastic
fibroma (AF) or ameloblastic fibro-odontomas (AFO). Pathological distinction of malignant transformation is essential for appropriate
treatment. The patient was a 28 years old man.  Since the primary tumor was excised, the mass recurred 2 years later. The recurrent
tumor was diagnosed as AFS. Chief complaint was pain in the right mandible. Computer tomography finding revealed multilocular intrabony
lesion with radiopaque substance in the primary lesion. In the recurrent lesion cortical bone destruction was found.  Microscopically,
both the primary and recurrent lesions showed benign ameloblastic follicles with myxoid or highly cellular mesenchymal proliferation.
The histological difference between primary and recurrent lesions were that foci of dental hard tissue composed of enamel and dentin 
were found only in the primary lesion, whereas nuclear pleomorphism was aggrevated in the recurrent lesion. The histological criteria
determining malignancy were discussed. 
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Ⅰ. INTRODUCTION      Ameloblastic fibrosarcoma (AFS) is an extremely rare 
malignant odontogenic tumor with the general features of 
a benign ameloblastic cells and malignant mesenchymal 
component1). To our knowledge, about 90 cases have been 
described in literature. 50% of all AFS are described as 
malignant transformation from AF2). Malignant transformation 
of AFO is rarely reported, but 2 cases of AFS transformed 
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from AFO were reported by Howell and Burkes3). The tumor 
usually develops in the mandible, presenting locally 
aggressive behavior causing pain and swelling4). Pathological 
distinction of malignant transformation is essential for 
appropriate treatment. The aim of this report is to present 
a new case of this rare entity with reference to diagnostic 
criteria of malignant transformation of AFO.
Ⅱ. CASE REPORT
The 28 years old man was referred to Dental Hospital 
of Yonsei University complaining of the right mandibular 
swelling. The panoramic radiograph of the primary lesion 
revealed an ill-defined multilocular intrabony lesion 
expanded from the right mandibular premolar to the angular 
area. Several foci of radiopaque substance were found. The 
root resorption of the involved teeth was found. Computer 
tomography showed expansion of the alveolar ridge with 
discontinuity of cortical bone and presence of radiopaque 
foci in the mandible (Fig. 1A and B). The surgical excision 
specimen showed benign epithelial components made up 
of columnar cells arranged in a palisaded pattern with a 
central area of stellate reticulum-like cells (Fig. 1C). The 
mesenchymal component showed a myxoid or highly 
cellular areas alternately; the myxoid portion composed of 
stellate or spindle shaped cells and the highly cellular portion 
composed of spindle or polygonal cells with slight nuclear 
atypia (Fig. 1E, F). Characteristically, foci of dental hard 
tissue composed of enamel and dentin were found (Fig. 1D). 
With these histological findings, the primary lesion was 
diagnosed as AFO with a note of the possibility of recurrence 
due to highly cellular area. 
During 2 years follow up period, pathological mandible 
fracture occurred and even after close reduction, the patient 
had discomfort in ascending ramus area. The computer 
tomography revealed multilocular intrabony lesion with 
cortical bone erosion (Fig. 2A). The tumor resection was 
conducted. Microscopically, the recurred mass revealed the 
similar histological findings with the primary tumor. 
Comparing to the primary tumor, the epithelial component 
of the recurred mass was reduced (Fig.2B, C). Particularly, 
the deposits of odontogenic hard tissue materials 
disappeared. In addition, highly cellular stromal portion 
showed nuclear pleomorphism (Fig. 2C, D, E). Despite the 
increased cellularity of the recurrent tumor, the mitotic index 
showed the same value with the primary tumor. The myxoid 
areas showed 0/10 high power field (hpf), whereas the 
highly cellular areas showed 3-4/10 hpf. The proliferating 
activity was measured by immunohistochemical staining for 
Ki-67. The primary antibody was purchased from Abcam 
(Cambridge, UK) and was diluted to be 1:100. The 
proliferating index showed the same value to be 6.8% in 
the primary tumor and 6.3% in the secondary tumor (Fig. 3). 
Considering increased cellularity and nuclear pleomorphism 
with devoid of odontogenic matrix, the recurred mass was 
diagnosed as AFS.
Ⅲ. DISCUSSION
The current 2005 WHO classification distinguished 
ameloblastic fibrodentino-and fibro-odontosarcomas (AFOS), 
separately from AFS. AFOS is defined as a tumor with 
histological features of AFS, together with dysplastic dentin 
and/or enamel/enameloid and dentin/dentinoid. Therefore, 
the recurrent tumor of this case was diagnosed as AFS because 
of no enameloid or dentinoid materials15). 
The definitive diagnosis of AFS has been established based 
on histopathologic evaluation of the mesenchymal component 
which usually demonstrates various features of malignancy 
including hypercellularity, nuclear pleomorphism, and mitotic 
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Fig. 1. (A and B) A panoramic radiograph and coronal computed tomographic sections of the mandible showing a neoplasm in 
2013. (C) AFO, sparsely cellular and myxoid dental papille like stroma surrounding benign epithelial component (x40). (D) Irregular 
masses of dental hard tissue composed of dentinoid structures accompanied with enamel matrix (x40). (E) Myxoid mesenchymal 
components showing spindle or stellate shaped cells (x200). (F) Closely packed mesenchymal component arranged hyperchromatic 
plump ovoid or spindle shaped cells (x200).
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Fig. 2. (A) The panoramic radiograph showing a multilocular intrabony lesion with evidence of breaking down of cortical bone 
(arrows) in 2015. (B) Ameloblastic follicles with highly cellular stroma (x40). (C) Myxoid mesenchymal tissue with hyperchromatic 
nucleated spindle cells (x200). (D) Closely packed mesenchymal component with pleomorphic polygonal cells with mitosis (x200) 
(inset x1000). (E) Highly cellular proliferation of spindle cells resembling fibrosarcoma, exhibiting moderate to marked nuclear 
pleomorphism and hyperchromatism (x200).
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Fig. 3. Ki-67 expression in the primary and recurrent tumors (x200) (inset x1000). (A) The primary tumor, AFO. (B) The recurrent 
tumor, AFS. 
figures6).  In our cases, the decision of malignancy of the 
recurrent tumor was not difficult based on relatively uniform 
high cellularity, nuclear pleomorphism with mitotic activity. 
However, the decision of biological behavior of the primary 
tumor was problematic. Although the primary tumor showed 
the stereotyped histological features of AFO such as definite 
differentiation of odontogenic matrix and benign natured 
ameloblastic epithelial islands and myxoid mesenchymal 
components, the primary tumor included highly cellular 
areas with mitotic activity, suggesting foci of malignant 
transformation.
The measurement of mitotic activity has been a histological 
criterion to determine malignancy in both carcinoma and 
sarcoma. For determining malignancy in fibroblast proliferating 
lesions, high mitotic counts (>1 per 10HPF) throughout a 
tumor should arouse suspicion of fibrosarcoma7). In terms 
of differentiating AFS from AF, most reports described that 
mitoses should not be a feature of AF8,9). The presence of 
a large number of cells in mitosis and atypical mitosis 
supports malignancy10,11). Considering the guideline of 
mitotic activity, the primary tumor included foci of malignant 
transformation. However, besides mitotic activity, other 
histological findings of the primary tumor were insufficient 
to be treated as malignancy. Furthermore, a wide spectrum 
of mitotic indices in AFS from 2/10 hpf to more than 100/10 
hpf have been reported. Furthermore, few mitoses can be 
present even in AF11), in contrast, there are reports that 
well-differentiated malignant areas are relatively hypocellular, 
with few mitotic figures in AFS12). 
Proliferating activity has been a reliable marker to 
confirm malignant tumors13). However, likewise to mitotic 
activities, proliferation activity varies among the reported 
cases from 47% to less than 10%11,13,14). In our cases, Ki67 
expression was found less than 10% in both primary and 
recurrent tumors. 
As a general rule, smooth muscle tumors without necrosis 
and little to no nuclear atypia may be diagnosed as 
“leiomyoma of uncertain malignant potential (UMP)” when 
the mitotic rate is <1/50 hpf (soft tissue location) or <10/50 
hpf (retroperitoneum) 15,16). That is, developmental site has 
been one of the main criteria for determining malignancy. 
For the decision of malignancy of odontogenic mesenchymal 
tumors, we proposed that odontogenic differentiation can 
be another factor to determine malignancy. In this case 
report, one crucial decision factor to determine malignancy 
was the fact that odontogenic differentiation shown in the 
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primary tumor was diminished with increased nuclear 
pleomorphism and cellularity in the recurrent tumor. 
Considering the primary tumor shown stereotyped AFO 
with transforming foci to sarcoma, AFO should be treated 
as one of the odontogenic tumors with the potentiality 
promoting to malignancy. Accumulated data with clinical 
follow-up of long periods should be required to establish 
more accurate criteria to determine malignancy. Currently, 
one year after the surgical procedure, the patient has been 
clinically disease-free. 
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